Adult patients diagnosed with unilateral stage 2 (persistent epithelial defect) and stage 3 (corneal ulcer) NK refractory to one or more conventional non-surgical treatments. Patients with Controlateral eye affected with stage 1 NK can be enrolled. MedDRA version: 16.1 Level: LLT Classification code 10032064 Term: Other forms of keratitis System Organ Class: 100000004853
Conditions
Interventions
Product Name: Recombinant Human Nerve Growth Factor (rhNGF)
Product Code: rhNGF
Pharmaceutical Form: Eye drops, solution
INN or Proposed INN: NA
CAS Number: NA
Current Sponsor code: rhNGF
Other descri
Sponsors
Dompé s.p.a
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients 18 years of age or older. 2. Patients with stage 2 (persistent epithelial defect, PED) or stage 3 (corneal ulcer) neurotrophic keratitis involving only one eye. Patients with Controlateral eye affected with stage 1 NK can be enrolled. 3. PED or corneal ulceration of at least 2 weeks duration refractory to one or more conventional non-surgical treatments for neurotrophic keratitis (e.g., preservative-free artificial tears, gels or ointments; discontinuation of preserved topical drops and medications that can decrease corneal sensitivity; therapeutic contact lenses). 4. Evidence of decreased corneal sensitivity (= 4 cm using the Cochet- Bonnet aesthesiometer) within the area of the PED or corneal ulcer and outside of the area of the defect in at least one corneal quadrant. 5. Best corrected distance visual acuity (BCDVA) score = 75 ETDRS letters, (= +0.2 LogMAR, = 20/32 Snellen or = 0.625 decimal fraction) in the affected eye. 6. No objective clinical evidence of improvement in the PED or corneal ulceration within the 2 weeks prior to study enrolment. 7. Only patients who satisfy all Informed Consent requirements may be included in the study. The patient and/or his/her legal representative must read, sign and date the Informed Consent document before any study-related procedures are performed. The Informed Consent form signed by patients and/or legal representative must have been approved by the IEC/IRB for the current study. 8. Patients must have the ability and willingness to comply with study procedures. 9. Patients must be eligible for the National Health Insurance (where applicable). Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 149 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 25
Exclusion criteria
Exclusion criteria: 1. Patients with stage 2 or 3 NK affecting both eyes. 2. Any active ocular infection (bacterial, viral, fungal or protozoal) or active ocular inflammation not related to NK in the affected eye. 3. Any other ocular disease requiring topical ocular treatment in the affected eye during the course of the study treatment period. No topical treatments other than the study medications provided by the study sponsor or allowed by the study protocol can be administered in the affected eye during the course of the study treatment periods. 4. Patients with severe vision loss in the affected eye with no potential for visual improvement in the opinion of the investigator as a result of the study treatment. 5. Schirmer test without anesthesia =3 mm/5 minutes in the affected eye. 6. Patients with severe blepharitis and/or severe meibomian gland disease in the affected eye. 7. History of any ocular surgery (including laser or refractive surgical procedures) in the affected eye within the three months before study enrolment. (An exception to the preceding statement will be allowed if the ocular surgery is considered to be the cause of the stage 2 or 3 NK). Ocular surgery in the affected eye will not be allowed during the study treatment period and elective ocular surgery procedures should not be planned during the duration of the follow-up period. 8. Prior surgical procedure(s) for the treatment of NK (e.g. complete tarsorraphy, conjunctival flap, etc) in the affected eye with the exception of amniotic membrane transplantation. Patients previously treated with amniotic membrane transplantation may only be enrolled two weeks after the membrane has disappeared within the area of the PED or corneal ulcer or at least six weeks after the date of the amniotic membrane transplantation procedure. Patients previously treated with Botox (botulinum toxin) injections used to induce pharmacologic blepharoptosis are eligible for enrolment only if the last injection was given at least 90 days prior to enrolment in the study. 9. Use of therapeutic contact lenses or contact lens wear for refractive correction during the study treatment periods in the eye with NK. Anticipated need for punctual occlusion during the study treatment period. 10. Patients with punctual occlusion or punctual plugs inserted prior to the study are eligible for enrolment provided that the punctual occlusion is maintained during the study. 11. Evidence of corneal ulceration involving the posterior third of the corneal stroma, corneal melting or perforation in the affected eye. 12. Presence or history of any ocular or systemic disorder or condition that might hinder the efficacy of the study treatment or its evaluation, could possibly interfere with the interpretation of study results, or could be judged by the investigator to be incompatible with the study visit schedule or conduct (e.g. progressive or degenerative corneal or retinal conditions, uveitis, optic neuritis, poorly controlled diabetes, autoimmune disease, systemic infection, neoplastic diseases). 13. Any need for or anticipated change in the dose of systemic medications known to impair the function of the trigeminal nerve (e.g. neuroleptics, antipsychotic and antihistamine drugs). These treatments are allowed during the study if initiated prior to 30 days before study enrolment provided they remain stable throughout the course of the study treatment periods. 14. Known hypersensitivity to one of the components of
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The objective of this study is to assess the safety and the efficacy of two dose regimens (10 µg/ml or 20 µg/ml 6 times a day) of recombinant human nerve growth factor (rhNGF) eye drops solution compared to vehicle for inducing a complete healing of stage 2 (persistent epithelial defect) and 3 (corneal ulcer) neurotrophic keratitis (NK) as measured by the investigator using corneal fluorescein staining.;Secondary Objective: Secondary objectives of the study are to assess the duration of complete healing, improvement in visual acuity and improvement in corneal sensitivity following treatment with rhNGF eye drops solution.;Primary end point(s): Percentage of patients achieving complete healing of the PED or corneal ulcer determined by corneal fluorescein staining at 4 weeks as defined by the investigator;Timepoint(s) of evaluation of this end point: At 4 weeks as defined by the investigator | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Consistent with the study design the secondary efficacy endpoints are presented according to the two study treatment periods: the 8 week controlled treatment period (Controlled Treatment Period) and the 46 or 52 week open-label follow-up period (Open-Label Follow-up Period). Secondary efficacy endpoints related to the Controlled Treatment Period • Percentage of patients experiencing complete healing of the PED or corneal ulcer at 6 and 8 weeks. • Mean change in BCDVA from baseline to Week 8. • Percentage of patients that achieve a 15 letter gain in BCDVA at 4 weeks, 6 weeks, 8 weeks. • Percentage of patients that achieve an improvement in corneal sensitivity as measured by the Cochet-Bonnet esthesiometer at 4, 6 and 8 weeks. • Percentage of patients experiencing deterioration (increase in lesion size = 1 mm, decrease in BCDVA by >5 ETDRS letters, progression in lesion depth to corneal melting or perforation, onset of infection) in stage 2 or 3 NK from baseline to Week 8. • Time to onset of deterioration from baseline to Week 8. • Investigator global evaluation of efficacy at 4, 6 and 8 weeks. Secondary efficacy endpoints related to the Open-label Follow-up Period: • Percentage of patients achieving complete healing of the PED or corneal ulcer by Week 8/16 that remain healed (i.e. no recurrence of the PED and/or corneal ulcer) at Weeks 20/28, 32/40, 44/52, 56/64. • Mean change in BCDVA in patients achieving complete healing of the PED or corneal ulcer by Week 8/16 at Weeks 20/28, 32/40, 44/52, 56/64. • Percentage of patients achieving complete healing of the PED or corneal ulcer by Week 8/16 that achieve a 15 letter gain in BCDVA weeks 20/28, 32/40, 44/52, 56/64. • Percentage of patients achieving complete healing of the PED or corneal ulcer by Week 8/16 with improved corneal sensitivity that show no change or further improvement at Weeks 20/28, 32/40, 44/52, 56/64. • Percentage of patients achieving complete heali | — |
Countries
Belgium, Germany, Hungary, Poland, Portugal, Spain, United Kingdom, United States
Contacts
Public ContactProject Development Direction
Dompé s.p.a
Outcome results
None listed